Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo
1. 系统已在2026-02-17 11:04:09对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: DOI: 10.1093/ejendo/lvaf043
其他信息:
G Ravel, X Gaume, C Berardet…
European Journal of …, 2025
academic.oup.com
Objective Acromegaly is an endocrine disorder caused by the hypersecretion of growth hormone (GH) by a benign tumor of the pituitary that leads to insulin-like growth factor-1 (IGF1) overproduction. In most patients, somatostatin analogs (SSAs), the current first-line medical therapy for acromegaly, do not normalize IGF1 levels. This study aims to investigate the pre-clinical efficacy of ALXN2420, a novel, small peptide antagonist of the growth hormone receptor (GHR), being developed as a combination therapy to SSAs to further …
